question: Compared to placebo what was the result of delayed-release DMF 240 mg TID on mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)?
context: In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).